2012-09-17 06:01:00 - Fast Market Research recommends "Trypanosomiasis - Pipeline Review, H2 2012" from Global Markets Direct, now available

Global Markets Direct's, 'Trypanosomiasis - Pipeline Review, H2 2012', provides an overview of the Trypanosomiasis therapeutic pipeline. This report provides information on the therapeutic development for Trypanosomiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Trypanosomiasis. 'Trypanosomiasis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463736_trypanosomiasis_pipeline_review_h2_20 ..


Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Trypanosomiasis.
* A review of the Trypanosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Trypanosomiasis pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Trypanosomiasis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Trypanosomiasis pipeline depth and focus of Trypanosomiasis therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Trypanosomiasis Therapeutic Products under Development, Key Players in Trypanosomiasis Therapeutics, Trypanosomiasis Pipeline Overview, Trypanosomiasis Pipeline, Trypanosomiasis Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Trypanosomiasis Overview
Therapeutics Development
An Overview of Pipeline Products for Trypanosomiasis
Trypanosomiasis Therapeutics under Development by Companies
Trypanosomiasis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Trypanosomiasis Therapeutics - Products under Development by Companies
Trypanosomiasis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Trypanosomiasis Therapeutics Development
Eisai Co., Ltd.
Merck Serono S.A.
iCo Therapeutics Inc.
MOLOGEN AG
Dafra Pharma International Ltd.
Anacor Pharmaceuticals, Inc.
aRigen Pharmaceuticals, Inc.
iBio, Inc.
PepTcell Limited
Trypanosomiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
E1224 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARA-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine For Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zitromax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine + Liposomal Amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AmBisome + Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amphotericin B Deoxycholate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Amphotericin B + Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Amphotericin B + Paromomycin Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463736&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.